Table 3 Reconstructed haplotypes and the association with risk of developing late skin toxicity (telangiectasia) with score ⩾2 after radiotherapy

From: Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer

Gene

Haplotype

Frequency

OR a

95% CI

All patients

    

TP53

GA1

0.71

1

 
 

GA2

0.03

1.02

0.29–3.63

 

CA1

0.16

1.20

0.79–1.82

 

CA2b

0.11

1.97

1.11–3.52

Patients without acute toxicity during radiotherapy c

TP53

GA1

0.71

1

 
 

GA2

0.02

0.68

0.13–3.60

 

CA1

0.16

1.15

0.71–1.85

 

CA2

0.12

2.78

1.44–5.37

Patients with acute toxicity during radiotherapy

TP53

GA1

0.71

1

 
 

GA2

0.04

1.10

0.09–13.41

 

CA1

0.17

1.47

0.52–4.17

 

CA2

0.09

0.52

0.11–2.53

All patients

    

XRCC1

CCGG

0.41

1

 
 

TCGG

0.12

1.15

0.66–2.00

 

TCGA

0.36

0.78

0.53–1.15

 

TTGG

0.05

0.51

0.21–1.24

 

Rared

0.07

0.56

0.26–1.20

XPD

GA

0.56

1

 
 

GC

0.09

1.25

0.64–2.46

 

AA

0.06

1.14

0.55–2.38

 

AC

0.29

1.09

0.74–1.62

  1. CI=confidence interval; NTD=normalised total dose; OR=odds ratio.
  2. aAdjusted for NTD, age the time of late toxicities evaluation, time since radiotherapy (months), clinic, acute skin toxicity, high blood pressure, allergy, pack-years (never, <20, ⩾20), skin type (always/moderate/seldom sunburn), clinic, marital status (single/divorced/widowed, married/partner).
  3. bA2 allele carries a duplication of 16 bp in intron 3.
  4. cP=0.06 for effect heterogeneity according to occurrence of acute skin toxicity.
  5. dComposed of haplotypes with frequencies below 5%.
Back to article page